Home › Hidradenitis Suppurativa
Hidradenitis Suppurativa clinical trials recruiting in the U.S.
29 studies for Hidradenitis Suppurativa are recruiting participants at sites across the United States.
Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.
Cities with the most studies
- Boston, MA9 studies
- Tampa, FL8 studies
- Phoenix, AZ6 studies
- Miami, FL6 studies
- New York City, NY5 studies
- New Orleans, LA5 studies
- Birmingham, AL5 studies
- Dallas, TX5 studies
- Philadelphia, PA4 studies
- Santa Clarita, CA4 studies
- Cleveland, OH4 studies
- The Bronx, NY4 studies
- Scottsdale, AZ4 studies
- Minneapolis, MN4 studies
- Durham, NC4 studies
- Baton Rouge, LA3 studies
- West Lafayette, IN3 studies
- Bowling Green, KY3 studies
- Louisville, KY3 studies
- Troy, MI3 studies
- Santa Monica, CA3 studies
- Boca Raton, FL3 studies
- Miami Gardens, FL3 studies
- Atlanta, GA3 studies
- Sandy Springs, GA3 studies
- Evanston, IL3 studies
- Baltimore, MD3 studies
- Detroit, MI3 studies
- St. Louis, MO3 studies
- Houston, TX3 studies
- San Francisco, CA3 studies
- Norfolk, VA3 studies
- Chicago, IL3 studies
- Huntington Beach, CA3 studies
- Portsmouth, NH3 studies
- Los Angeles, CA3 studies
By state
- Alabama5 studies
- Arizona8 studies
- California13 studies
- Florida11 studies
- Georgia8 studies
- Illinois6 studies
- Indiana6 studies
- Kentucky6 studies
- Louisiana7 studies
- Maryland3 studies
- Massachusetts10 studies
- Michigan7 studies
- Minnesota4 studies
- Missouri6 studies
- New Hampshire3 studies
- New Jersey3 studies
- New York8 studies
- North Carolina5 studies
- Ohio6 studies
- Pennsylvania7 studies
- South Carolina3 studies
- Texas9 studies
- Utah3 studies
- Virginia3 studies
Recently updated studies
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT07665437ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Sep 24, 2026 · NCT07783542A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07225569Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07828860Regulation of Inflammatory Genes in Hidradenitis Suppurativa
RecruitingObservational study
Ages 18 to 89 · All sexes · Updated Sep 21, 2026 · NCT05507125A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 18, 2026 · NCT06888193Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Sep 15, 2026 · NCT07049575Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06855498Targeting Nociceptors in Hidradenitis Suppurativa
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Sep 10, 2026 · NCT05403710Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06058520Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06326476Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07170917Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2
Ages 12 to 17 · All sexes · Updated Aug 6, 2026 · NCT07213973A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 22, 2026 · NCT07384975Myriad™ Augmented Soft Tissue Reconstruction Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT05243966The Safety and Efficacy of Roflumilast Foam in HS
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT07263230A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated May 29, 2026 · NCT07287644Pelashield™ PainGuard™ vs Restrata® in HS Surgery
Recruiting
Ages 18 and older · All sexes · Updated May 22, 2026 · NCT07316192Radiotherapy for Refractory Hidradenitis Suppurativa
Recruiting
Ages 18 and older · All sexes · Updated May 15, 2026 · NCT07414550Clinical and Biological Characteristics of Hidradenitis Suppurativa
RecruitingObservational studyHealthy volunteers welcome
Ages 13 and older · All sexes · Updated May 4, 2026 · NCT03967600Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
RecruitingObservational study
Ages 10 and older · All sexes · Updated Apr 29, 2026 · NCT04115566A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
RecruitingObservational study
Ages 18 to 71 · All sexes · Updated Apr 16, 2026 · NCT07123038A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 6, 2026 · NCT07244263The Ohio State University Dermatology Biorepository
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Feb 27, 2026 · NCT03146676A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RecruitingPhase 2
Ages 18 to 90 · All sexes · Updated Dec 23, 2025 · NCT07077902From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.